Sleep Disturbances in Smith-Magenis Syndrome
0
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
VP
Vanda PharmaceuticalsWASHINGTON, DC
1 programData collection of sleep disturbances in individuals with SMSN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Vanda PharmaceuticalsData collection of sleep disturbances in individuals with SMS
Clinical Trials (1)
Total enrollment: 1,000 patients across 1 trials
Development of Clinical Database of Individuals With Smith-Magenis Syndrome and Sleep Disturbances
Start: Jan 2016Est. completion: Dec 20301,000 patients
N/ARecruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 1,000 patients
1 companies competing in this space